Holen Sie sich die Stockscreener-App
0.00
100.00%
-41.03
Handel nachbörslich:
41.06
41.06
+
Schlusskurs vom Vortag:
$41.03
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$5.25B
Einnahmen:
$1.11B
Nettoeinkommen (Verlust:
$133.27M
KGV:
0.00
EPS:
1.0006
Netto-Cashflow:
$37.47M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$41.14
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
0.00 | 5.25B | 1.11B | 133.27M | 37.47M | 1.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Eingeleitet | Roth Capital | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS Suspended by Cantor Fitzgerald -- Rating Remains Neutral - GuruFocus
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals - BioPharm International
Biogen upgraded to Hold after Apellis acquisition boosts prospects despite challenges. - Pluang
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins - TechStock²
Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) - Stock Titan
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - Yahoo Finance
Biogen Completes Acquisition of Apellis Pharmaceuticals - Sahm
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen Acquires Apellis Pharmaceuticals (APLS) to Enhance Growth Potential - GuruFocus
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Biogen–Apellis (APLS) deal triggers GC’s cash, CVR and option changes - Stock Titan
Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders - Stock Titan
Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Biogen (APLS counterparty) closes Apellis tender offer and merger with cash and CVR deal - Stock Titan
Biogen stock (US09062X1037): closes $5.3B Apellis deal - AD HOC NEWS
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over - TechStock²
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):